Levobunolol, HydrochlorideCAS: 27912-14-7
MF: C17H26ClNO3
MW: 327.84
A β-adrenoceptor antagonist.

Levobunolol, Hydrochloride (CAS 27912-14-7)

Levobunolol, Hydrochloride | CAS 27912-14-7 is rated 5.0 out of 5 by 1.
  • y_2020, m_1, d_18, h_19
  • bvseo_bulk, prod_bvrr, vn_bulk_3.0.4
  • cp_1, bvpage1
  • co_hasreviews, tv_0, tr_1
  • loc_en_US, sid_211734, prod, sort_[SortEntry(order=SUBMISSION_TIME, direction=DESCENDING)]
  • clientName_scbt
  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getAggregateRating, 220ms
  • REVIEWS, PRODUCT
5
1
4
0
3
0
2
0
1
0
Synonym: Vistagan; Akbeta
Application: A β-adrenoceptor antagonist
CAS Number: 27912-14-7
Molecular Weight: 327.84
Molecular Formula: C17H26ClNO3
* Refer to Certificate of Analysis for lot specific data (including water content).
Submit a review for this product and receive 15 CruzCredits

Levobunolol, Hydrochloride is a non-selective β-AR (β-adrenoceptor) antagonist.


References

1. Kaplan, HR, et al., 1971. Oral-adrenoreceptor blocking activity of bunolol and its optical isomers. European journal of pharmacology. 16(2): 237-40. PMID: 4405784
2. DiCarlo,F.J., et al., 1977. Metabolism of I-bunolol. Clinical pharmacology & therapeutics. 22(6): 858-63. PMID: 336256

Physical State :
Solid
Solubility :
Soluble in Dimethyl Sulfoxide, Hot Ethanol, Methanol and Water
Storage :
Store at -20° C
Melting Point :
209-211° C
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
PubChem CID :
5284409
SMILES :
CC(C)(C)NC[[email protected]@H](COC1=CC=CC2=C1CCCC2=O)O.Cl

Download SDS (MSDS)

Certificate of Analysis

Adobe Acrobat Reader is required to reliably view,
print and comment on PDF documents

  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getContent, 109ms
  • QUESTIONS, PRODUCT
  • bvseo-msg: The resource to the URL or file is currently unavailable.;
Rated 5 out of 5 by from Rothwell Rothwell, CE. et al. (PubMed) evaluated the chronic toxicity and carcinogenicity of Levobunolol, a non-selective -adrenoceptor antagonist, in Swiss mice and Wistar rats. In rats, significant body weight gain suppression occurred at 5, 30, and 180 mg/kg. Brown discoloration of perianal fur and steel-gray discoloration of hairless skin were evident in high-dose rats. A generalized steel-gray discoloration of internal organs and tissues occurred in the 30 and 180 mg/kg groups. No other differences between treated and control groups were evident. -SCBT Publication Review
Date published: 2015-04-25
  • y_2020, m_1, d_18, h_19
  • bvseo_bulk, prod_bvrr, vn_bulk_3.0.4
  • cp_1, bvpage1
  • co_hasreviews, tv_0, tr_1
  • loc_en_US, sid_211734, prod, sort_[SortEntry(order=SUBMISSION_TIME, direction=DESCENDING)]
  • clientName_scbt
  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getReviews, 16ms
  • REVIEWS, PRODUCT

Santa Cruz Biotechnology, Inc. is a world leader in the development of products for the biomedical research market. Call us Toll Free at 1-800-457-3801.
Copyright © 2007-2019 Santa Cruz Biotechnology, Inc. All Rights Reserved. "Santa Cruz Biotechnology", and the Santa Cruz Biotechnology, Inc. logo, "Santa Cruz Animal Health", "San Juan Ranch", "Supplement of Champions", the San Juan Ranch logo, "Ultracruz", "Chemcruz", "Immunocruz", "Exactacruz", and "EZ Touch" are registered trademarks of Santa Cruz Biotechnology, Inc.
All trademarks are the property of their respective owners.